These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9831296)

  • 41. Localisation of VIP-binding sites exhibiting properties of VPAC receptors in chromaffin cells of rainbow trout (Oncorhynchus mykiss).
    Montpetit CJ; Shahsavarani A; Perry SF
    J Exp Biol; 2003 Jun; 206(Pt 11):1917-27. PubMed ID: 12728013
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat.
    Baun M; Hay-Schmidt A; Edvinsson L; Olesen J; Jansen-Olesen I
    Eur J Pharmacol; 2011 Nov; 670(1):186-94. PubMed ID: 21914446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
    Uchida D; Tatsuno I; Tanaka T; Hirai A; Saito Y; Moro O; Tajima M
    Ann N Y Acad Sci; 1998 Dec; 865():253-8. PubMed ID: 9928019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distribution of the VPAC2 receptor in peripheral tissues of the mouse.
    Harmar AJ; Sheward WJ; Morrison CF; Waser B; Gugger M; Reubi JC
    Endocrinology; 2004 Mar; 145(3):1203-10. PubMed ID: 14617572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Construction of chimeras between human VIP1 and secretin receptors: identification of receptor domains involved in selectivity towards VIP, secretin, and PACAP.
    Du K; Nicole P; Couvineau A; Laburthe M
    Ann N Y Acad Sci; 1998 Dec; 865():386-9. PubMed ID: 9928035
    [No Abstract]   [Full Text] [Related]  

  • 46. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery.
    Schmidt DT; Rühlmann E; Waldeck B; Branscheid D; Luts A; Sundler F; Rabe KF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Oct; 364(4):314-20. PubMed ID: 11683518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
    Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
    Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
    Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Electrical and mechanical effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide in the rat colon involve different mechanisms.
    Plujà L; Fernández E; Jiménez M
    Eur J Pharmacol; 2000 Feb; 389(2-3):217-24. PubMed ID: 10688987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interactive mechanisms among pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide, and parathyroid hormone receptors in guinea pig cecal circular smooth muscle cells.
    Motomura Y; Chijiiwa Y; Iwakiri Y; Ochiai T; Nawata H
    Endocrinology; 1998 Jun; 139(6):2869-78. PubMed ID: 9607796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
    Tsutsumi M; Claus TH; Liang Y; Li Y; Yang L; Zhu J; Dela Cruz F; Peng X; Chen H; Yung SL; Hamren S; Livingston JN; Pan CQ
    Diabetes; 2002 May; 51(5):1453-60. PubMed ID: 11978642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aging-Induced Modulation of Pituitary Adenylate Cyclase-Activating Peptide- and Vasoactive Intestinal Peptide-Induced Vasomotor Responses in the Arteries of Mice.
    Ivic I; Solymar M; Fulop BD; Hashimoto H; Toth G; Tamas A; Juhasz T; Koller A; Reglodi D
    J Vasc Res; 2017; 54(6):359-366. PubMed ID: 29131060
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
    Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
    Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M; Couvineau A; Rouyer-Fessard C
    Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptides (PACAP27) and PACAP38) protect CD4+CD8+ thymocytes from glucocorticoid-induced apoptosis.
    Delgado M; Garrido E; Martinez C; Leceta J; Gomariz RP
    Blood; 1996 Jun; 87(12):5152-61. PubMed ID: 8652828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat.
    Bertrand G; Puech R; Maisonnasse Y; Bockaert J; Loubatières-Mariani MM
    Br J Pharmacol; 1996 Feb; 117(4):764-70. PubMed ID: 8646426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hypophysiotropic action of pituitary adenylate cyclase-activating polypeptide (PACAP) in the goldfish: immunohistochemical demonstration of PACAP in the pituitary, PACAP stimulation of growth hormone release from pituitary cells, and molecular cloning of pituitary type I PACAP receptor.
    Wong AO; Leung MY; Shea WL; Tse LY; Chang JP; Chow BK
    Endocrinology; 1998 Aug; 139(8):3465-79. PubMed ID: 9681497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.